Hypoparathyroidism

Top drugs studied for this disease

EMA withdrawal · 2026-07-10
EMA Withdrawn: Natpar (parathyroid hormone) — Takeda Pharmaceuticals International AG Ireland Branch
EU EMA has withdrawn Natpar (parathyroid hormone) by Takeda; therapeutic area hypoparathyroidism with previous conditional and orphan design…
CLINICAL_TRIALS withdrawal · 2022-10-10
Clinical Trial Update: A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism [Phase 3]
A Phase 3 clinical trial evaluating rhPTH(1-84) in Japanese participants with chronic hypoparathyroidism was withdrawn.